Sugi Predict

Sugi Predict / Targets / IRS1

IRS1

Insulin receptor substrate 1 · P35568 · IRS1 on Sugi Atlas →

829 patent compounds predicted against IRS1, 465 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL282664 SCHEMBL282664 1.00 3/20
SCHEMBL282905 SCHEMBL282905 1.00 3/20
SCHEMBL283045 SCHEMBL283045 1.00 3/20
SCHEMBL12829989 SCHEMBL12829989 0.79 3/20
SCHEMBL287001 SCHEMBL287001 0.78 3/20
SCHEMBL288913 SCHEMBL288913 0.78 3/20
SCHEMBL19532783 SCHEMBL19532783 0.78 3/20
SCHEMBL1413821 SCHEMBL1413821 0.76 3/20
SCHEMBL1413996 SCHEMBL1413996 0.75 3/20
SCHEMBL283324 SCHEMBL283324 0.73 3/20
SCHEMBL282734 SCHEMBL282734 0.73 3/20
SCHEMBL282715 SCHEMBL282715 0.72 3/20
SCHEMBL11891689 SCHEMBL11891689 0.72 3/20
SCHEMBL283691 SCHEMBL283691 0.70 3/20
SCHEMBL283819 SCHEMBL283819 0.69 3/20
SCHEMBL19532791 SCHEMBL19532791 0.68 3/20
SCHEMBL5831475 SCHEMBL5831475 0.67 3/20
SCHEMBL282521 SCHEMBL282521 0.65 3/20
SCHEMBL284048 SCHEMBL284048 0.65 3/20
SCHEMBL5830619 SCHEMBL5830619 0.63 3/20

Clinical trials — most relevant to IRS1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway PHASE4COMPLETED
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance PHASE4UNKNOWN
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes PHASE4COMPLETED
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer PHASE4WITHDRAWN
Molecular Mechanisms of Type 2 Diabetes Mellitus PHASE4COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus PHASE2/PHASE3UNKNOWN
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate PHASE2/PHASE3WITHDRAWN
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes PHASE2RECRUITING
Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer PHASE2COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer PHASE1/PHASE2COMPLETED
MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer PHASE2COMPLETED
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus PHASE2COMPLETED
Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans PHASE1COMPLETED
Insulin Receptor Substrate 1 (IRS-1) Regulation in Insulin Resistance PHASE1COMPLETED
IRS Proteins and Trastuzumab Resistance nanCOMPLETED
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH nanCOMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients nanUNKNOWN
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome nanUNKNOWN
AR, IGF-IR, IR and Peripheral Artery Disease nanUNKNOWN
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome nanCOMPLETED
Polycystic Ovary Syndrome in Type 1 Diabetes nanNOT_YET_RECRUITING
Observational Study of Insulin Resistance and Muscle Wasting After Burn Injury nanWITHDRAWN
IVF Outcome in Polycystic Ovary Syndrome Patients nanUNKNOWN
The Influence of Genetic Variations in ELAPOR1 or ELAPOR2 on Insulin Secretion and Glucose Regulation in Humans nanUNKNOWN
Novel Therapy for Glucose Intolerance in HIV Disease nanCOMPLETED
Marker of Brain Insulin Resistance in AD Prognosis nanNOT_YET_RECRUITING
Growth Hormone Signaling in Vivo in Humans nanCOMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Microvascular Dysfunction and the Development of Whole-body Insulin Resistance nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a IRS1 binder may also engage these)

ProteinNameSimilarity
P35569 — 1.000 P35569 →
Q28224 — 1.000 Q28224 →
P35570 — 1.000 P35570 →
P81122 — 0.996 P81122 →
P84770 — 0.995 P84770 →
Q91615 — 0.987 Q91615 →
Q8C180 — 0.985 Q8C180 →
Q9Z1S8 — 0.985 Q9Z1S8 →
Q9Y4H2 — 0.985 Q9Y4H2 →
Q5RJW5 — 0.985 Q5RJW5 →
Q62925 — 0.982 Q62925 →
P91621 — 0.981 P91621 →
Q9DF49 — 0.981 Q9DF49 →
Q6P4Y6 — 0.981 Q6P4Y6 →
Q6DN90 — 0.979 Q6DN90 →
FRS2 Fibroblast growth factor receptor substrate 2 0.979 landscape →
Q9EQH1 — 0.979 Q9EQH1 →
Q5R7W7 — 0.978 Q5R7W7 →
Q9UQC2 — 0.978 Q9UQC2 →
O77086 — 0.978 O77086 →
GAB1 GRB2-associated-binding protein 1 0.978 landscape →
Q07E15 — 0.977 Q07E15 →
Q66L44 — 0.977 Q66L44 →
A6QLU3 — 0.977 A6QLU3 →
AXIN2 Axin-2 0.977 landscape →
Q09YI1 — 0.977 Q09YI1 →
A2AEV7 — 0.976 A2AEV7 →
Q62136 — 0.976 Q62136 →
Q8K070 — 0.976 Q8K070 →
P98083 — 0.976 P98083 →